OSR (NASDAQ:OSRH) Announces Quarterly Earnings Results

OSR (NASDAQ:OSRH) issued its quarterly earnings results on Wednesday. The company reported ($0.09) earnings per share for the quarter, Zacks reports. OSR had a negative net margin of 619.82% and a negative return on equity of 13.53%.

OSR Price Performance

OSRH traded down $0.03 during trading on Wednesday, hitting $0.62. The company’s stock had a trading volume of 1,996,083 shares, compared to its average volume of 17,752,332. The firm’s 50 day moving average price is $0.53 and its 200-day moving average price is $0.58. The stock has a market cap of $21.64 million, a PE ratio of -0.48 and a beta of 0.86. OSR has a twelve month low of $0.38 and a twelve month high of $1.79.

Institutional Trading of OSR

A hedge fund recently bought a new stake in OSR stock. Susquehanna International Group LLP acquired a new position in shares of OSR Holdings, Inc. (NASDAQ:OSRH) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 79,807 shares of the company’s stock, valued at approximately $43,000. Susquehanna International Group LLP owned about 0.37% of OSR as of its most recent SEC filing. 55.30% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of OSR in a report on Friday, March 27th. Wall Street Zen upgraded OSR from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.